C4 Therapeutics Statistics
Total Valuation
C4 Therapeutics has a market cap or net worth of $492.10 million. The enterprise value is $248.51 million.
| Market Cap | 492.10M |
| Enterprise Value | 248.51M |
Important Dates
The last earnings date was Tuesday, August 11, 2026, before market open.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
C4 Therapeutics has 123.03 million shares outstanding. The number of shares has increased by 58.30% in one year.
| Current Share Class | 123.03M |
| Shares Outstanding | 123.03M |
| Shares Change (YoY) | +58.30% |
| Shares Change (QoQ) | +3.67% |
| Owned by Insiders (%) | 1.03% |
| Owned by Institutions (%) | 85.66% |
| Float | 94.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.04 |
| Forward PS | 26.15 |
| PB Ratio | 1.99 |
| P/TBV Ratio | 1.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.45, with a Debt / Equity ratio of 0.23.
| Current Ratio | 5.45 |
| Quick Ratio | 5.29 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -48.14% and return on invested capital (ROIC) is -23.34%.
| Return on Equity (ROE) | -48.14% |
| Return on Assets (ROA) | -19.25% |
| Return on Invested Capital (ROIC) | -23.34% |
| Return on Capital Employed (ROCE) | -32.47% |
| Weighted Average Cost of Capital (WACC) | 18.33% |
| Revenue Per Employee | $336,913 |
| Profits Per Employee | -$975,154 |
| Employee Count | 104 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, C4 Therapeutics has paid $121,000 in taxes.
| Income Tax | 121,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +53.85% in the last 52 weeks. The beta is 2.95, so C4 Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 2.95 |
| 52-Week Price Change | +53.85% |
| 50-Day Moving Average | 3.94 |
| 200-Day Moving Average | 2.97 |
| Relative Strength Index (RSI) | 53.56 |
| Average Volume (20 Days) | 2,499,628 |
Short Selling Information
The latest short interest is 30.43 million, so 24.73% of the outstanding shares have been sold short.
| Short Interest | 30.43M |
| Short Previous Month | 23.82M |
| Short % of Shares Out | 24.73% |
| Short % of Float | 32.19% |
| Short Ratio (days to cover) | 9.21 |
Income Statement
In the last 12 months, C4 Therapeutics had revenue of $35.04 million and -$101.42 million in losses. Loss per share was -$0.91.
| Revenue | 35.04M |
| Gross Profit | 30.25M |
| Operating Income | -101.03M |
| Pretax Income | -101.30M |
| Net Income | -101.42M |
| EBITDA | -99.45M |
| EBIT | -101.03M |
| Loss Per Share | -$0.91 |
Balance Sheet
The company has $253.66 million in cash and $56.86 million in debt, with a net cash position of $243.59 million or $1.98 per share.
| Cash & Cash Equivalents | 253.66M |
| Total Debt | 56.86M |
| Net Cash | 243.59M |
| Net Cash Per Share | $1.98 |
| Equity (Book Value) | 247.27M |
| Book Value Per Share | 2.01 |
| Working Capital | 214.66M |
Cash Flow
In the last 12 months, operating cash flow was -$84.87 million and capital expenditures -$523,000, giving a free cash flow of -$85.39 million.
| Operating Cash Flow | -84.87M |
| Capital Expenditures | -523,000 |
| Depreciation & Amortization | 1.58M |
| Net Borrowing | n/a |
| Free Cash Flow | -85.39M |
| FCF Per Share | -$0.69 |
Margins
Gross margin is 86.34%, with operating and profit margins of -288.34% and -289.44%.
| Gross Margin | 86.34% |
| Operating Margin | -288.34% |
| Pretax Margin | -289.09% |
| Profit Margin | -289.44% |
| EBITDA Margin | -283.82% |
| EBIT Margin | -288.34% |
| FCF Margin | n/a |
Dividends & Yields
C4 Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -58.30% |
| Shareholder Yield | n/a |
| Earnings Yield | -20.61% |
| FCF Yield | -17.35% |
Analyst Forecast
The average price target for C4 Therapeutics is $13.33, which is 233.25% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.33 |
| Price Target Difference | 233.25% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | -20.09% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
C4 Therapeutics has an Altman Z-Score of -1.87 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.87 |
| Piotroski F-Score | 4 |